Research Library
How GHK-Cu Works: Copper Peptide Research Explained
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva and urine. Plasma levels fall with age, which prompted research into skin remodelling, wound repair and gene expression. It has the strongest human evidence base of the classic repair peptides, largely from dermatology.
Summary
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva and urine. Plasma levels fall with age, which prompted research into skin remodelling, wound repair and gene expression. It has the strongest human evidence base of the classic repair peptides, largely from dermatology.
Last reviewed 2026-09-01
What it is
GHK is a tripeptide with the sequence Gly-His-Lys that binds copper(II) with high affinity. The complex, GHK-Cu, is the biologically active form studied in most papers.
GHK was identified in 1973 by Loren Pickart while investigating why human plasma from younger donors improved liver tissue function in culture more than plasma from older donors.
Endogenous. It is present in plasma at roughly 200 ng/mL at age 20 and around 80 ng/mL by age 60, and is also released from the extracellular matrix during tissue injury.
The age-related decline, the copper-transport role, and later gene-expression profiling showing broad transcriptional effects made it one of the most studied small peptides in dermatology.
How it works
In plain terms
GHK carries copper — a metal several repair enzymes need — into cells, and appears to switch skin repair genes back toward a younger pattern.
Technical detail
GHK-Cu functions as a copper(II) chaperone, supplying the cofactor for lysyl oxidase and superoxide dismutase. Broad transcriptomic analyses report modulation of over 4,000 human genes, with upregulation of collagen I, III and IV, elastin, decorin and glycosaminoglycan synthesis, and downregulation of TGF-β1-associated fibrotic signalling and several inflammatory mediators. It also stimulates dermal fibroblast proliferation and angiogenesis in vitro.
Pathways involved
- Copper(II) chaperoning to lysyl oxidase and SOD
- Collagen I/III/IV and elastin gene upregulation
- Glycosaminoglycan and decorin synthesis
- Antioxidant and metal-detoxification gene programmes
- Fibroblast proliferation and dermal angiogenesis
Current research
Laboratory research
In-vitro work in fibroblast and keratinocyte cultures reliably shows increased collagen synthesis and matrix protein expression. Gene-expression array studies underpin most mechanistic claims.
Animal research
Rodent, rabbit and porcine wound models report accelerated closure, improved tensile strength and reduced scarring; hair follicle enlargement has been reported in rodent studies.
Human research
Controlled cosmetic dermatology trials — typically 8 to 12 weeks, facial or periorbital application — report measurable improvements in skin density, wrinkle depth and elasticity versus vehicle. Sample sizes are modest and many studies are industry-funded. Copper peptide creams are widely sold as cosmetics rather than medicines.
Ongoing research
Most current activity is cosmetic-formulation research rather than registered clinical trials.
What is being investigated
- Collagen and elastin synthesis in ageing skin
- Wound closure and scar quality in animal models
- Hair follicle size in rodent studies
- Antioxidant enzyme support via copper delivery
- Anti-inflammatory gene expression profiles
These are research directions reported in the literature, not established effects or recommendations.
Risks, limitations and unknowns
Read this section before the rest
- Copper is a required but narrowly regulated trace metal; excessive exposure is toxic, and copper-handling disorders such as Wilson's disease are a clear contraindication for supplementation
- Human evidence is concentrated in cosmetic endpoints with small sample sizes and frequent industry funding
- Systemic (non-topical) use in humans is essentially unstudied
- Gene-expression breadth is often overstated in marketing; a transcriptional change is not a clinical outcome
- Formulation stability and actual delivered concentration vary widely between products
Evidence ratings
Laboratory studies
StrongReproducible matrix-protein and gene-expression effects.
Animal studies
StrongConsistent wound-model findings across several species.
Human studies
ModerateMultiple controlled topical cosmetic trials; small and often funded.
Long-term safety
LimitedTopical use well tolerated short-term; systemic use unstudied.
Comparisons
Verified peptide suppliers
References
- [1]GHK-Cu — indexed literature — PubMed, 1973–present
- [2]GHK and human gene expression — PubMed, 2010–present
- [3]Copper peptide skin trials — PubMed, 2000–present
- Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.
Frequently asked questions
What is GHK-Cu?+
A copper-bound tripeptide (glycyl-L-histidyl-L-lysine) that occurs naturally in human plasma and is studied for skin and wound repair.
Is GHK-Cu natural?+
Yes. It is endogenous, and plasma concentrations decline with age from roughly 200 ng/mL at 20 to about 80 ng/mL at 60.
How does GHK-Cu work?+
It chaperones copper to enzymes such as lysyl oxidase and superoxide dismutase, and modulates a broad set of genes governing collagen, elastin and antioxidant systems.
Does GHK-Cu have human evidence?+
Yes, more than most research peptides — several controlled topical dermatology trials report improvements in skin density and wrinkle depth, though with small samples.
Is GHK-Cu approved as a medicine?+
No. It is regulated as a cosmetic ingredient in most markets, not as a drug.
Can GHK-Cu cause copper toxicity?+
Topical cosmetic exposure delivers small amounts, but anyone with a copper-handling disorder such as Wilson's disease should avoid supplemental copper entirely.
Does GHK-Cu affect hair?+
Rodent studies report increased follicle size, and small human observations exist, but controlled human trials for hair endpoints are lacking.
Why does GHK-Cu turn products blue?+
The copper(II) complex is intrinsically blue; the colour is a property of the coordinated metal, not a defect.
What is the difference between GHK and GHK-Cu?+
GHK is the peptide alone; GHK-Cu is the peptide with copper bound. Most reported biological activity requires the copper complex.
Continue your research
Independent publication · Research summaries only
Evidence-first
Every claim tied to a study
Cited sources
PubMed · ClinicalTrials.gov
Evidence tiers
Lab, animal and human kept apart
No commerce
Nothing sold or sponsored here
Editorial standards
Reviewed before publication
Research library
Structured compound summaries
Plain language
Mechanisms explained simply
Research use only
Not medical advice